VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2 (Q57904509)

From Wikidata

Jump to navigation Jump to search

article by Apostolos C. Ziogas et al published 25 May 2011 in International Journal of Cancer

Language	Label	Description	Also known as
English	VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2	article by Apostolos C. Ziogas et al published 25 May 2011 in International Journal of Cancer

Statements

scholarly article

0 references

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2 (English)

0 references

cancer research

0 references

1 reference

based on heuristic

inferred from title

Athanasios Dimopoulos

12

object named as

Meletios A. Dimopoulos

0 references

author name string

Apostolos C. Ziogas

1

0 references

Nikos G. Gavalas

2

0 references

Marinos Tsiatas

3

0 references

Ourania Tsitsilonis

4

0 references

Ekaterini Politi

5

0 references

Evangelos Terpos

6

0 references

Alexandros Rodolakis

7

0 references

George Vlahos

8

0 references

Nikolaos Thomakos

9

0 references

Dimitrios Haidopoulos

10

0 references

Aristidis Antsaklis

11

0 references

Aristotle Bamias

13

0 references

language of work or name

0 references

publication date

25 May 2011

0 references

International Journal of Cancer

0 references

130

0 references

4

0 references

857-864

0 references

Angiogenic inhibitors: a new therapeutic strategy in oncology

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Tumorigenesis and the angiogenic switch

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Immunosuppressive networks in the tumour environment and their therapeutic relevance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

VEGFR2 is selectively expressed by FOXP3high CD4+ Treg.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26094

21 January 2018

Identifiers

10.1002/IJC.26094

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57904509&oldid=1552125499"